{
    "clinical_study": {
        "@rank": "99119", 
        "arm_group": [
            {
                "arm_group_label": "Aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin, 100mg, Q.D, p.o, 2yr"
            }, 
            {
                "arm_group_label": "Cilostazol", 
                "arm_group_type": "Experimental", 
                "description": "cilostazol, 100mg, B.I.D, p.o, 2yr"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients of vascular cognitive impairment-no dementia (VCIND) in one group is prescribed\n      cilostazol,in the other group is prescribed aspirin. Evaluate both of them in cognitive\n      function, MRI and other sides at given time. The investigators hypothesize that cilostazol\n      is more efficient and safer than aspirin in patients with VCIND."
        }, 
        "brief_title": "Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Mild Cognitive Impairment", 
        "condition_browse": {
            "mesh_term": "Cognition Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged between 50-80, both gender\uff1b\n\n          2. Small vessel disease and associated cognitive impairment, diagnosed as VCIND\uff1b\n\n          3. Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are\n             acceptable.\n\n          4. Normal hepatic and renal function.\n\n          5. With good compliance.\n\n        Exclusion Criteria:\n\n          1. Aged above 80 or less than 50.\n\n          2. Dementia.\n\n          3. Cerebral infarction(>2cm).\n\n          4. Major vascular lesion. (stenosis>50%).\n\n          5. Cardiac cerebral infarction.\n\n          6. Intracerebral Hemorrhage.\n\n          7. Clinical manifestations cannot attribute to small vessel disease.\n\n          8. Major depression or dysfunction in speech, visual ability, hearing or aphasia that\n             would interfere with the cognitive assessment.\n\n          9. Severe systematic organic impairment(cardiac, hepatic, renal dysfunction).\n\n         10. Thrombocytopenic Purpura.\n\n         11. History of hemorrhage in digestive system or surgery in past 3 months.\n\n         12. Previously on cilostazol treatment for more than 3 month.\n\n         13. Allergic to aspirin or cilostazol.\n\n         14. Enrolled in other clinical trials in past 3 months.\n\n         15. Lack of informed consent or compliance.\n\n         16. Contraindications for MRI scan."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01862575", 
            "nct_id": "NCT01872858", 
            "org_study_id": "jianhuifu2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aspirin", 
                "description": "Aspirin, 100mg, Q.D, p.o, 2yr", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cilostazol", 
                "description": "cilostazol, 100mg, B.I.D, p.o, 2yr", 
                "intervention_name": "Cilostazol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Cilostazol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 5, 2013", 
        "location": {
            "contact": {
                "email": "tan11711@hotmail.com", 
                "last_name": "Jie Tang", 
                "phone": "+8618818210880"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200040"
                }, 
                "name": "Dept. of Neurology, Huashan Hospital, Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "scores in Montreal Cognitive Assessment\uff0cMini-Mental Status Examination, Clinal Dementia Rating\uff0ctrail making test, similarity test, Stroop test.", 
            "measure": "changes in cognitive function", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, 3month, 6month, 1year, and 2year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872858"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Huashan Hospital", 
            "investigator_full_name": "Jianhui Fu", 
            "investigator_title": "Department of Neurology, Huashan Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "including cerebral infarct, cerebral hemorrhage, transient ischemic attack.", 
                "measure": "Number of Participants with Incident cerebral vascular event", 
                "safety_issue": "Yes", 
                "time_frame": "3month, 6month, 1year and 2year"
            }, 
            {
                "description": "intercellular adhesion molecules(ICAM), thrombomodulin, tissue factor(TF), tissue factor plasma inhibitor\uff0cTFPI, etc.", 
                "measure": "Changes of peripheral inflammatory markers level", 
                "safety_issue": "No", 
                "time_frame": "baseline,  2year"
            }, 
            {
                "measure": "The progression of cerebral white matter lesion and lacunar infarction", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 3month, 6month, 1year and 2year"
            }, 
            {
                "description": "cerebral volume , lacune infarct, white matter lesion, micro-bleed, apparent diffusion coefficient(ADC) .", 
                "measure": "changes in MRI-diffused tension image(DTI)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 2year"
            }
        ], 
        "source": "Huashan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Huashan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}